Healthy Aging and Senile Dementia

总体项目摘要 健康老龄化和老年痴呆症（HASD）研究的首要目标是确定 这表明认知正常的老年人即将出现有症状的阿尔茨海默病（AD）。在 为了实现这一目标，HASD还将研究这些预测因素在非洲裔美国人之间是否存在差异 和非西班牙裔白人，受睡眠的影响，或者可能被遗传变异抵消， 出现症状性AD。最后，HASD将评估一种评估认知表现的新方法 通过智能手机应用程序在自然环境中进行。 为了实现这些目标，HASD将评估和跟踪一个丰富的表型队列，包括 认知正常的老年人（约75%）和早期症状性AD患者（约25%）。纵向 评估方案包括标准和新颖的临床和认知措施，六天的家庭睡眠， 研究，大脑磁结构成像研究，大脑正电子发射断层扫描研究， 揭示了AD的大脑标志，淀粉样β蛋白斑块和tau蛋白沉积，以及血液检查， 基因研究和脑脊液中淀粉样蛋白β和tau水平。五个核心（行政、 临床、生物统计学、神经病理学[包括生物流体实验室]和成像）将支持四个 实现HASD科学目标的项目： 项目1：“AD整个病理生物学连续体的分子生物标志物特征” 项目2：“睡眠和食欲素：从临床前到轻度症状进展的潜在标志物 老年痴呆症” 项目3：“剖析复原力的遗传结构” 项目4：“基于智能手机的”突发“认知评估”

Overall Project Summary The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine the factors that signal the imminent development of symptomatic Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non-Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application. To accomplish these goals, HASD will assess and follow a richly phenotyped cohort that includes both cognitively normal older adults (~75%) and those with early-stage symptomatic AD (~25%). The longitudinal assessment protocol includes standard and novel clinical and cognitive measures, a six-day in-home sleep study, magnetic structural imaging studies of the brain, positron emission tomography studies of the brain to reveal the cerebral hallmarks of AD, amyloid-beta plaques and tau deposition, and examination of blood for genetic studies and of cerebrospinal fluid for levels of amyloid-beta and tau. Five Cores (Administration, Clinical, Biostatistics, Neuropathology [includes the Biofluids Laboratory], and Imaging) will support four Projects that carry out the scientific aims of HASD: Project 1: “Characterization of Molecular Biomarker Profiles of AD throughout its Pathobiological Continuum” Project 2: “Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer Disease” Project 3: “Dissecting the Genetic Architecture of Resilience” Project 4: “Smartphone-Based `Burst' Cognitive Assessments”